Kids & teens (for parents) · Texas
Studies for children and teens in Texas
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
128 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Ionis Pharmaceuticals, Inc.
- Location
- Dallas, TX + 4 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Fort Worth, TX + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent…
Bausch Health Americas, Inc.
- Location
- Austin, TX + 22 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Austin, TX + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Garland, TX + 12 other US sites
- Eligibility basics
- Ages 13–17
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Plano, TX + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Hoffmann-La Roche
- Location
- Dallas, TX + 9 other US sites
- Eligibility basics
- Ages 4 mo–2
- RecruitingPhase 2
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Scholar Rock, Inc.
- Location
- Dallas, TX + 11 other US sites
- Eligibility basics
- Up to age 2
- RecruitingPhase 2
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Tyra Biosciences, Inc
- Location
- Dallas, TX + 11 other US sites
- Eligibility basics
- Ages 3–10
- RecruitingPhase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
GlaxoSmithKline
- Location
- Dallas, TX + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- El Paso, TX + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Edinburg, TX + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Regeneron Pharmaceuticals
- Location
- Fort Worth, TX + 12 other US sites
- Eligibility basics
- Ages 6 mo–6
- RecruitingPhase 3
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- Houston, TX + 16 other US sites
- Eligibility basics
- Ages 3–12
- RecruitingPhase 3
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Agios Pharmaceuticals, Inc.
- Location
- Dallas, TX + 3 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
Agios Pharmaceuticals, Inc.
- Location
- Dallas, TX + 4 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC
- Location
- Fort Worth, TX + 8 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Coppell, TX + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Austin, TX + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Beaumont, TX + 27 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Coppell, TX + 26 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 4
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
CorMedix Therapeutics
- Location
- Fort Worth, TX + 5 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- San Antonio, TX + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Houston, TX + 9 other US sites
- Eligibility basics
- Ages 12–17